contact us krjpencn


Our Events

현재 위치: > 뉴스현황 > Our Events

  • 09


    Medicilon appoints Dr. Hong Wan as Vice President of Pharmacokinetics and Bioanalysis Department

    Recently, Shanghai Medicilon Inc. (stock code: 688202.SH) (Medicilon) announced the appointment of Dr. Hong Wan as Vice President of Pharmacokinetics and Bioanalysis Department.

  • 08


    Qing Ruan and his team examined Medicilon

    On August 4, 2021, Mr. Qing Ruan, Deputy Director of Shanghai Municipal Development and Reform Commission, and his team visited Shanghai Medicilon Inc. (Medicilon) at Chuansha Park for examination.  Professor Shuangqing Peng, CSO of Medicilon; Yaoliang Zhang, Director of the Administration Department; and Nanmei Zhou, Director of the Public Affairs accompanied the examination and organized a symposium.

  • 06


    New Drugs and AI Innov Forum was successful held

    On June 18, the 12th Shanghai Medicilon symposium “New Drug + AI Innov Forum” was held in Shanghai Disneyland Hotel.  

  • 06


    Medicilon assists Palaatu to obtain clinical approval for PA9159 for rhinitis

    On June 2, 2021, the National Medical Products Administration (NMPA) officially announced that the glucocorticoid drug PA9159 nasal spray was approved for clinical use. The PA9159 developed by Zhejiang Palaatu Pharmaceutical Company (Palaatu) is for seasonal and perennial allergic rhinitis.

  • 05


    Safety assessment lab of process chemistry

    Adhering to "Innovation-Driven, Quality First", Medicilon has established a laboratory research platform focused on evaluating the safety of chemical processes to provide clients with customized, accurate and reliable testing data and safety assessments.